46. Malignant rheumatoid arthritis Clinical trials / Disease details

Clinical trials : 4,356 / Drugs : 2,567 - (DrugBank : 415) / Drug target genes : 192 - Drug target pathways : 228

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05392127 (ClinicalTrials.gov)	July 15, 2022	23/5/2022	A Pharmacokinetic Study to Evaluate the Drug Interaction Between SHR0302 and CYP Substrates in Healthy Volunteers	A Single-center, Open-label, Single-arm, Fixed-sequence Study to Evaluate the Pharmacokinetic Effects of SHR0302 Tablets on Substrates of CYP3A4, CYP2C8, CYP2C9, CYP2C19 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302 Tablets;Drug: Midazolam Maleate Tablets;Drug: Warfarin Sodium Tablets;Drug: Omeprazole Enteric Capsules;Drug: Vitamin K1 Tablets;Drug: Repaglinide Tablets	Jiangsu HengRui Medicine Co., Ltd.	NULL	Completed	18 Years	45 Years	Male	24	Phase 1	China
2	NCT05404724 (ClinicalTrials.gov)	June 25, 2022	31/5/2022	Study on the Pharmacokinetic Effect of Itraconazole on SHR0302 Tablets in Healthy Subjects	Study on the Pharmacokinetic Effects of Single-centered, Open, Single-arm, Fixed-sequence Itraconazole on SHR0302 Tablets in Healthy Subjects	Rheumatoid Arthritis	Drug: itraconazole ? SHR0302 tablets	Jiangsu HengRui Medicine Co., Ltd.	NULL	Completed	18 Years	45 Years	Male	14	Phase 1	China
3	NCT04333771 (ClinicalTrials.gov)	July 31, 2020	2/4/2020	A Study to Evaluate the Efficacy and Safety of SHR0302 in Patients With Rheumatoid Arthritis	A Multicenter, Randomized, Double-blind, Placebo-controlled Phase 3 Clinical Study to Evaluate the Efficacy and Safety of SHR0302 in Moderate to Severe Active Rheumatoid Arthritis Subjects With Inadequate Response to csDMARDs.	Rheumatoid Arthritis	Drug: SHR0302;Drug: Placebo	Jiangsu HengRui Medicine Co., Ltd.	NULL	Recruiting	18 Years	75 Years	All	600	Phase 3	China
4	NCT03254966 (ClinicalTrials.gov)	November 24, 2017	15/8/2017	Study of SHR0302 Tablets (SHR0302) as Monotherapy in Active Rheumatoid Arthritis (RA) Patients	Randomized, Double-blind, Placebo-controlled, Multicenter, Phase II Study to Assess the Safety and Efficacy of SHR0302 in Patients With Moderate to Severe Active Rheumatoid Arthritis	Rheumatoid Arthritis	Drug: SHR0302;Drug: Placebo	Jiangsu HengRui Medicine Co., Ltd.	NULL	Completed	18 Years	70 Years	All	194	Phase 2	China
5	NCT02892370 (ClinicalTrials.gov)	August 2016	2/9/2016	Effect of a High-fat Meal on the Pharmacokinetics of SHR0302 and Mass Balance Study in Healthy Subjects	An Open Label, Randomized, Two-period, Crossover Study to Assess the Effect of Food on SHR0302 and Mass Balance in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302	Jiangsu HengRui Medicine Co., Ltd.	NULL	Recruiting	18 Years	45 Years	Male	14	Phase 1	China
6	NCT02665910 (ClinicalTrials.gov)	May 2016	24/1/2016	Multiple Doses Escalation Study of SHR0302 in Rheumatoid Arthritis (RA) Patients	A Phase I, Randomized, Placebo-Controlled, Multiple Doses Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Patients With RA	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.	NULL	Not yet recruiting	18 Years	70 Years	Both	48	Phase 1	China
7	NCT02423538 (ClinicalTrials.gov)	April 2015	7/4/2015	First-in-Human Single Ascending Dose of SHR0302	A Phase I, Randomized, Placebo-Controlled, Single Dose Escalation Study to Investigate Safety, Pharmacokinetics and Pharmacodynamics of SHR0302 in Healthy Volunteers	Rheumatoid Arthritis	Drug: SHR0302;Drug: SHR0302 placebo comparator	Jiangsu HengRui Medicine Co., Ltd.	NULL	Active, not recruiting	18 Years	45 Years	Both	64	Phase 1	China